Please select the eligibility criteria that correspond to the clinical trial below.
Title: Trial of the Use of Antenatal Corticosteroids in Developing Countries
Brief Summary: Multi-country two-arm, parallel cluster randomized controlled trial to reduce neonatal mortality through increasing the rate of antenatal corticosteroid administration to eligible women.


Options:
A: Inclusion Criteria:

The pregnant women will be eligible for the trial entry if all following criteria are met:

* administration of a course of antenatal corticosteroid at least 7 days before the trial entry
* gestational age is less than 33.0 weeks 6 days\*
* very high risk of premature delivery\*\*
* none of the following therapies complications or therapies maternal long term systemic corticosteroid therapy severe clinical chorioamnionitis (maternal fever, increased CRP or another acute phase protein, uterine tenderness) lethal disease of the fetus
* informed consent obtained
* premature rupture of membranes is not contraindication for the trial entry

  \*Gestational age will be calculated from the mother's last menstrual period and confirmed by ultrasound before 20 weeks' gestation. In case the discrepancy in the estimates exceeds two weeks, ultrasound date is accepted.

  \*\*Very high risk of premature delivery is described as follows:
* elective delivery within within 4-48 hours, as indicated by the obstetrician on the basis of the clinical status of the mother and/or the fetus
* very high risk of spontaneous delivery within 4-48 hours, i.e.
* cervix is open \> 3 cm
* contractions of the uterus at 5-10 min intervals
* rupture of the membranes after the first course of ANC
* fetal and/or maternal indication for elective premature delivery or cesarean section
B: This is an intent-to-treat design and thus all pregnancy outcomes of women who deliver in the study clusters and provide consent will be collected. Cluster-level inclusion criteria include

* At least 250 deliveries per year.
* Birth attendants within the health cluster will be consented to participate

Participant-level inclusion criteria include all pregnant women living in and delivering in the study cluster who:

* Are between 24 and 36 weeks GA;
* Present with signs of preterm labor, amniotic fluid leakage, hemorrhage, or hypertension;
* Provide consent for injection or present to a facility where it is standard of care.

Exclusion Criteria:

* There will not be any specific exclusion criteria for clusters or participants.
C: Inclusion Criteria:

* (1) Age over 18 years
* (2) Twin pregnant women at 34weeks 0days to 36weeks 5days of gestation
* (3) At risk for preterm birth such as preterm labor, preterm prematrue rupture of membrane or maternal-fetal indications that need preterm delivery. Preterm labor is defined as regular uterine contractions with or without the following symptoms; pelvic pressure, backache, increased vaginal discharge, menstrual-like cramps, bleeding/show, cervical changes
* (4) Availability of written informed consent.

Exclusion Criteria:

* (1) Gestational age before 34weeks 0days or after 36weeks 6days
* (2) Lethal major fetal anomaly, fetal distress or fetal death in utero
* (3) Expected to deliver within 12 hours; for example, advanced cervical dilatation (\>8cm) in preterm labor or active phase labor (cervical dilatation\>4cm) in preterm premature rupture of membranes
* (4) History of a previous administration of ACS before 34weeks of gestation for fetal lung maturation
* (5) Administration of systemic steroid for medical indications
* (6)Diagnosis of clinical chorioamnionitis Fever \>37.8 and the presence of two more following conditions: uterine tenderness, foul-odored vaginal discharge, maternal leukocytosis(\>1500), maternal tachycardia(\>100) or fetal tachycardia(\>160)
D: Inclusion Criteria:

* Singleton pregnancy
* Patient Having receipt the first injection of betamethasone and pregnancy term \< 32 weeks of gestation
* Age \> 18 years
* Patient affiliated to a social security regime

Exclusion Criteria:

* Chromosomal aberrations and major fetal malformations
* Cervical dilatation ≥ 4 cm and of cervical length ≥20mm.
* Patient who have already received a first course of betamethasone
* first intravenous injection of betamethasone

Answer: B